DIA Biosimilars 2013

Cell Therapeutics

Cell Therapeutics appoints Benner as new CMO

Friday, June 15, 2012 11:11 AM

Cell Therapeutics, a Seattle-based company focused on translating science into novel cancer therapies, has appointed former OncoMed Pharmaceuticals executive, Steven E. Benner, M.D., M.H.S., as its executive vice president and chief medical officer.

More... »

Cenduit: Now with Patient Reminders

Cell Therapeutics acquires pacritinib from S*BIO

Friday, April 20, 2012 12:57 PM

Seattle-based Cell Therapeutics (CTI) has purchased worldwide rights to pacritinib from S*BIO, Singapore’s first fully integrated drug discovery company.

More... »

CRF Health – eCOA Forum

Cell Therapeutics, Chroma Therapeutics ink license, co-development pact

Thursday, March 17, 2011 11:57 AM

Cell Therapeutics (CTI) and Chroma Therapeutics have entered into a co-development and license agreement providing CTI with exclusive marketing and co-development rights to Chroma's drug candidate tosedostat in North, Central and South America.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs